Gene Logic, Selling Preclinical Division, Puts All Eggs in Drug Repositioning Basket

Faced with a 69-percent drop in third-quarter revenues, Gene Logic has once again repositioned its business strategy by putting its preclinical division on the block, refocusing its genomics arm, and pinning its hopes on its drug repositioning activities.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.